• Non-clinical drug discovery: Developed, executed, and assessed novel therapeutics against BoNT and neurodegenerative diseases.• Drug metabolism and pharmacokinetics/pharmacodynamics: Spearheaded and executed studies on non-clinical drug pharmacokinetics/pharmacodynamics in vitro and in vivo.• Internal and external communication: Spearheaded development and drafting of approved grant (SBIR (co-IP)); IACUC applications; internal company SOPs and safety documents; compiling and reviewing data and reports for future IND FDA filing; company research overviews and future directions (monthly and yearly)• Management: Supervised research personal in daily and weekly projects.

• Non-clinical drug discovery: Developed, executed (production, purification and activation), and assessed novel therapeutic against BoNT.• Internal communication: Developed and defined batch record and associated SOPs for GMP manufacturing of drug substances. Development of SOPs for primary neuronal culture isolation and assays.

Projects: Development, establishment, and validation of novel influenza therapeutic interfering particles (TIPs). Development and establishment of reverse genetics system for coronavirus.Responsibilities/skills include but not limited to: procurement, safety, and assistant human resource director, initial testing of biological component of viroreactor, developed and lead team in order to establish reverse genetics system for coronavirus (30kbp genome), supervised senior scientists and summer interns in multiple ongoing projects including but not limited to: adenovirus delivery system, influenza TIP library production, influenza virus TIP mobilization and interference assay platforms, stable cell line production, coronavirus reverse genetics system

Projects: Development, establishment, and validation of novel influenza therapeutic interfering particles (TIPs).Responsibilities/skills include but not limited to: procurement, safety, development and establishment of the in-house influenza reverse genetics system

Project: Development of tandem shRNA cloning vectorResponsibilities/skills include but not limited to: Development and implementation of a cloning strategy for production of tandem shRNA, construction and validation of over 500 clones in an arrayed shRNA library

• Development and establishment of phage techniques and screening tools from the ground up for validated collapse of phage display libraries resulting in viable candidates within 6 months• Validating phage display clones for further in vivo testing resulting in over 30 novel peptides• Performed NGS on screened phage pools to confirm library collapse• Development and establishment of cell based ELISA assay in order to decrease screening time by 2 months• Performed small scale mammalian cell culture protein production in order to validate functional candidates• Oversaw indirect reports daily in a team of 15 in order to ensure project progress

• Performed virus infections over multiple rounds to assess viral evolution• Prepared RNA-seq sample to assess viral evolution resulting in observed hot spots demonstrating viraladaptation• Maintained laboratory and consumable inventory by overseeing purchasing of all supplies• Supervised summer intern which resulted in Westinghouse presentation

• Molecular cloning and reverse genetics of numerous influenza viral segments contain miRNAs resulting in viral RNA and miRNAs produced simultaneously• Molecular cloning and reverse genetics of numerous influenza viral segments contain miRNA targets resulting in tissue specific attenuation of viral RNA• Molecular cloning and reverse genetics of splicing variants of influenza in order to determine influenza life cycle control.• Utilization on small animal models in order to determine extent of recombinant influenza virus morbidity• Numerous publications of research including in one first and one co-first author paperChua MA, Schmid S, Perez JT, Langlois RA, tenOever BR. Influenza A virus exploits splicing to coordinate the timing of infection. Cell Reports 2013 Jan 31;3:1-7.Varble A*, Chua MA*, Perez JT, Manicassamy B, García-Sastre A, tenOever BR. Engineered RNA viral synthesis of microRNAs. Proc Natl Acad Sci U S A. 2010 Jun 22;107 (25):11519-24.* Authors contributed equally to this work

• Maintaining laboratory and consumable inventory and overseeing purchasing of all supplies needed resulting in $15,000 decrease in spending within the first year• Develop standard operating procedures and maintain records to comply with regulatory requirements such as radioactivity use and EPA/OSHA disposal of chemical guidelines• Supervised summer intern and oversaw their daily activities to meet deadlines• Develop and administered $3 million budget in order to maximize funding